Chronic Kidney Disease 5D, Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Deficiency
Conditions
Brief summary
1. Study content: This is a multicentre, double-blind, randomised controlled study to determine the optimal dose and duration of treatment for the correction of vitamin D insufficiency or deficiency in patients with CKD5d; to investigate whether vitamin D supplementation delays the increase in PTH levels in this group of patients; and to investigate the effects on changes in CKD-MBD-related markers, cardiovascular complications, cognitive function in this group of patients. 2. Study procedure: Based on the inclusion and exclusion of the patients, the study was conducted in accordance with the following criteria 2. Study procedure: Eligible subjects were screened according to inclusion and exclusion criteria and randomly divided into three groups: high-dose vitamin D group, low-dose vitamin D group and control group. Baseline data were collected before the intervention and each group was given different doses of regular vitamin D2 softgels or placebo and followed up. 25(OH)D, PTH, blood Ca, and blood P levels were measured every month; bone metabolism markers, FGF23, and blood counts, liver function, kidney function, lipids, and blood glucose were measured every 3 months; the prevalence of vascular calcification, the incidence of cardiovascular events, and changes in cognitive function scale scores were assessed 6 months after the intervention.
Interventions
DRUGHigh-dose vitamin D2 softgels
5000U/capsule of vitamin D2 soft capsule; High-dose VD group 50,000 U/week, 5 vitamin D2 softgels given twice a week each time; 25(OH)D \> 80ng/ml after 3 months of intervention or within 3 months in both groups, changed to 5,000 U/ weekly maintenance until the full 6 months of intervention. To prevent unmasking, the maintenance dose was still given twice weekly (the first time 1 vitamin D2 capsule + 4 placebo capsules were given and the second time 5 placebo capsules were given)
DRUGlow-dose vitamin D2 softgels
5000U/capsule of vitamin D2 soft capsule; low-dose VD group 25,000 U/week, 3 vitamin D2 softgels + 2 placebo in the first dose, 2 vitamin D2 softgels + 3 placebo in the second dose, 25(OH)D \> 80ng/ml after 3 months of intervention or within 3 months in both groups, changed to 5,000 U/ weekly maintenance until the full 6 months of intervention. To prevent unmasking, the maintenance dose was still given twice weekly (the first time 1 vitamin D2 capsule + 4 placebo capsules were given and the second time 5 placebo capsules were given);
DRUGplacebo
placebo was filled with excipients (aniseed ether, refined vegetable oil), and the shape and size were the same as vitamin D2 soft capsule.the control group was given placebo, 5 placebo capsules twice weekly for 6 months of the intervention. The medication was dispensed by a designated person (not the investigator) in advance and independently according to the patient's medication number (only the drug number was provided on the outer packaging).
Sponsors
First Affiliated Hospital Xi'an Jiaotong University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years. 2. Patients with chronic kidney disease stage 5d who have been on haemodialysis for 3 months or more 3. 5 ng/mL \< 25(OH)D \< 30 ng/mL (liquid phase tandem mass spectrometry). 4. 130 pg/ml \< PTH \< 600 pg/ml (electrochemiluminescence method). 5. serum phosphorus \< 1.78 mmol/L. 6. Good compliance with the treatment requirements formulated for the study. 7. informed consent from the subject.
Exclusion criteria
1. Patients who are prepped for or have undergone renal transplantation or parathyroidectomy. 2. taking vitamin D, active vitamin D or analogues and other drugs that may affect 25(OH)D levels within 3 months prior to enrolment 3. Treatment affecting PTH results (e.g. cenacaser, etc.) within 3 months prior to enrolment 4. Serum calcium \> 2.55 mmol/L 5. Patients who are pregnant or likely to become pregnant, breastfeeding or planning to become pregnant during the study period 6. known prior or concomitant serious illness or medical condition such as malignancy, human immunodeficiency virus, severe gastrointestinal or liver disease, intestinal malabsorptive disease, hepatitis or cardiovascular events that may worsen or shorten life expectancy and/or interfere with participation in the study 7. History of neurological/psychiatric disease, including psychosis or dementia, or any other reason that is unlikely to result in adherence to treatment or follow-up plans. 8. Known or suspected allergy to any component of the study drug. 9. Ongoing participation in other clinical studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differences in changes in PTH levels from baseline to 6 months of intervention | baseline，at 6 months intervention |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of 25(OH)D >30ng/ml at 3 months of intervention | at 3 months intervention | — |
| Trends in changes in 25(OH)D levels from baseline to intervention at 1months、2months、3months、4months、5months、6months | baseline，at 1，2，3，4，5，6 months intervention | — |
| Incidence of cardiovascular events after 6 months of intervention | baseline，at 6 months intervention | — |
| Change in prevalence of vascular calcification at 6 months of intervention | baseline，at 6 months intervention | We used cardiac ultrasound and lateral abdominal views to look for vascular calcification |
| Change in Montreal Cognitive Assessment Scale scores at 6 months of intervention | baseline，at 6 months intervention | A total score of 30 on this scale, with a score of ≥26 indicating normal; a score of \<26 indicates the presence of cognitive impairment: 18-26 for mild cognitive impairment, 10-17 for moderate cognitive impairment and \<10 for severe cognitive impairment |
| Trends in blood calcium levels at 1 month, 2 months, 3 months, 4 months, 5 months and 6 months of intervention | baseline，at 1，2，3，4，5，6 months intervention | — |
| Trends in blood phosphorus levels at 1 month, 2 months, 3 months, 4 months, 5 months and 6 months of intervention | baseline，at 1，2，3，4，5，6 months intervention | — |
| Differences in changes in PTH levels from baseline to intervention at 1months、2months、3months、4months、5months | baseline，at 1，2，3，4，5 months intervention | — |
| Trends in Osteocalcin(OC) levels at 3 and 6 months of intervention | baseline，at 3，6 months intervention | — |
| Trends in Precollagen type I amino-terminal peptide(PINP) levels at 3 and 6 months of intervention | baseline，at 3，6 months intervention | — |
| Trends in β specific collagen degradation products(β-CTX) levels at 3 and 6 months of intervention | baseline，at 3，6 months intervention | — |
| Trends in ALP levels at 3 and 6 months of intervention | baseline，at 3，6 months intervention | — |
| Incidence of fractures at 6 months of intervention | baseline，at 6 months intervention | Ask if the patient had a fracture during the intervention, the site of the fracture and the type of fracture |
| Incidence of falls at 6 months of intervention | baseline，at 6 months intervention | Ask if the patient has fallen during the intervention, the number of falls and the reasons for them |
| Trends in FGF23 levels at 3 and 6 months of intervention | baseline，at 3，6 months intervention | — |
Countries
China
Contacts
Primary ContactHongli Jiang, Professor
Outcome results
None listed